Investment Rating - The report initiates coverage with an "Accumulate" rating for Samsung Medical (601567.SH) [1][3] Core Insights - Samsung Medical has established a dual business model focusing on smart power distribution and medical services, maintaining a leading and stable market share in the domestic power distribution sector while expanding its overseas presence in Europe, the Middle East, and Latin America [1][7] - The company is well-positioned to benefit from the high demand for smart power distribution overseas, particularly in Europe, where the penetration rate of smart meters is still low, presenting significant growth opportunities [7][30] - The domestic power distribution market is expected to accelerate, with the company maintaining a strong competitive position and benefiting from ongoing network upgrades [7][41] - The rehabilitation medical sector is identified as a blue ocean market, with the company expanding its network of rehabilitation hospitals in response to increasing domestic demand [7][18] Financial Data and Valuation - Total revenue is projected to grow from 11,463 million yuan in 2023 to 21,506 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 18% [2] - Operating profit is expected to increase from 2,270 million yuan in 2023 to 3,008 million yuan in 2027, with a notable growth of 97% in 2023 [2] - Net profit attributable to shareholders is forecasted to rise from 1,904 million yuan in 2023 to 2,576 million yuan in 2027, reflecting a growth of 101% in 2023 [2] - The company’s price-to-earnings (PE) ratio is projected to decrease from 19.7 in 2023 to 14.6 in 2027, indicating an improving valuation [2] Company Overview - Samsung Medical was established in 2007, evolving from a company with over 30 years of experience in the electric meter industry, and has since diversified into power distribution and medical services [11][12] - The company has a concentrated ownership structure, with the founder and chairman holding over 40% of the shares [12][15] Business Segments - The smart power distribution segment accounts for approximately 80% of total revenue, with a consistent growth rate of 20-30% since 2022 [18][22] - The medical services segment is expanding through investments and acquisitions, with a focus on high-quality rehabilitation services [18][24] Market Dynamics - The overseas demand for power distribution is robust, with significant investments planned in the European power grid, particularly in modernization and digitalization [41][43] - Emerging markets are experiencing rapid infrastructure development, with increasing participation from Chinese companies in projects across Latin America and the Middle East [46][48]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 CSG Smart Science & Technology Co., Ltd. 科大智能科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監 會」）的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代 表 閣下知悉、接納並向本公司、其聯席保薦人、整體協調人、顧問或承銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅據呈交香港公司註冊處處長 註冊的本公司招股章程作出投資決定，有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根 據本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其補充 ...

Group 1 - The core business of Samsung Medical (601567) consists of two main segments: smart power distribution and medical services [1] - The company has clarified that it is not involved in the field of controllable nuclear fusion [1]

Group 1 - The company, Samsung Medical (601567.SH), stated that its main business consists of two segments: smart power distribution and medical services, and it does not engage in the field of controllable nuclear fusion [1][2]

Core Viewpoint - Samsung Medical confirmed that it does not engage in the field of controllable nuclear fusion, focusing instead on its main business areas of smart power distribution and medical services [1] Group 1 - Investors inquired about Samsung Medical's involvement in controllable nuclear fusion [1] - Samsung Medical's response clarified its primary business operations [1]

Group 1 - The core business of Samsung Medical (601567.SH) consists of two main segments: smart power distribution and medical services [1] - The company has clarified that it is not involved in the field of controllable nuclear fusion [1]

Core Viewpoint - Samsung Medical reported a decline in Q3 revenue and net profit, primarily due to slow domestic order deliveries and low-margin overseas orders, but expects recovery in gross margins and prices with upcoming tenders [1][2]. Financial Performance - Q3 revenue reached 3.108 billion yuan, down 9.56% year-on-year and 28.42% quarter-on-quarter; net profit attributable to shareholders was 298 million yuan, up 55.22% year-on-year and down 59.74% quarter-on-quarter [1]. - For the first three quarters of 2025, revenue was 11.08 billion yuan, up 6.19% year-on-year; net profit was 1.528 billion yuan, down 15.85% year-on-year, with a gross margin of 28.46%, down 7.74 percentage points [2]. Order Backlog and Market Expansion - As of Q3 2025, the total order backlog reached 17.914 billion yuan, up 14.69% year-on-year, with overseas distribution orders at 2.169 billion yuan, up 125.45% [2]. - The company is focusing on expanding its presence in Europe, the Middle East, and Latin America, achieving initial orders in several countries, including Hungary and Romania [2]. Business Development - The company maintains a leading position in domestic network business and is actively expanding its customer base outside the network, targeting large clients in the renewable energy sector and new market segments [3]. Profit Forecast and Valuation - The company has adjusted its net profit forecasts for 2025-2027 downwards by 16.23%, 15.21%, and 10.60% respectively, with expected net profits of 2.261 billion, 2.765 billion, and 3.491 billion yuan [4]. - The target price is set at 28.32 yuan, maintaining a "buy" rating based on adjusted earnings multiples [4].

Core Viewpoint - Samsung Medical (601567.SH) has developed an integrated solution in the field of smart energy management to meet the needs of domestic and international customers [1] Group 1 - The company has formed a comprehensive solution in smart power distribution, which includes smart meters, smart terminals, communication modules, system software, transformers, box-type substations, switch cabinets, power boxes, photovoltaic/wind power box transformers, charging piles, inverters, and energy storage-related products [1] - Currently, the company does not have any military-related business [1]

Core Viewpoint - Samsung Medical (601567.SH) has developed an integrated solution in the field of smart energy management to meet the needs of domestic and international customers, which includes various products and systems [1] Group 1 - The company has formed a comprehensive solution in smart power distribution, which encompasses smart meters, smart terminals, communication modules, system software, transformers, box-type substations, switch cabinets, power boxes, photovoltaic/wind power box transformers, charging piles, inverters, and energy storage-related products [1] - Currently, the company does not have any military-related business [1]

Core Viewpoint - Weisheng Holdings (03393) has seen a significant stock price increase of over 25% following the release of its interim results, with a current trading price of 11.19 HKD and a trading volume of 47.63 million HKD [1] Financial Performance - The company reported a revenue of 4.39 billion RMB, representing a year-on-year increase of 17.34% [1] - Net profit attributable to shareholders reached 440 million RMB, marking a year-on-year increase of 32.81% [1] Market Analysis - CICC's report indicates that Weisheng Holdings' performance exceeded expectations, driven by expansion in external markets such as communications, and better-than-industry performance in domestic meter deliveries and collections [1] - Citigroup's report highlights that the net profit for the first half of the year rose by 32.8% to 440 million RMB, surpassing the market's expectation of a full-year profit increase of 28.3% to 906 million RMB [1] Business Segments - The revenue from the smart distribution and utilization system and solutions (ADO) segment grew by 9.2% year-on-year, primarily due to strong product demand from overseas data centers [1] - Management maintains a dividend payout ratio of 50% for 2025 and capital expenditure guidance, anticipating strong performance in new orders from overseas data centers, which is expected to support a 21% growth in ADO business revenue for the year [1]